Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 9, 2025Molecular TherapyOpen Access

Innate Immune Cells in Chimeric Antigen Receptor Therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

MJMarius JassaudLZLydia Ziane-ChaoucheMDMarie Duhamel

Discussion

Loading...

Member takes

Overview

Review examines CAR-engineered innate immune cells in cancer treatment, highlighting cytokine release syndrome challenges and future strategies.

Key Points

  • CAR therapies, especially CAR-T cells, have transformed treatment for blood cancers but face challenges with solid tumors.
  • The review emphasizes the potential of innate immune cells, demonstrating advantages like lower risk of graft-versus-host disease and natural tumor-homing abilities.
  • Innovative strategies using CAR-engineered innate immune cells could lead to better outcomes with solid tumor treatments, potentially lessening immune-related toxicities.
  • Future directions in CAR therapy will explore combinatorial approaches, with innate immune cells playing a key role in shaping cancer immunotherapy.

Cite This Study

Jassaud et al. (2025) studied this question.

synapsesocial.com/papers/68e7d631bd66d359be6265fahttps://doi.org/10.1016/j.ymthe.2025.10.003
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Engineering Innate Immunity: Recent Advances and Future Directions for CAR-NK and CAR–Macrophage Therapies in Solid Tumors2025 · 24 citations
  2. 2Expanding Immunotherapy Beyond CAR T Cells: Engineering Diverse Immune Cells to Target Solid Tumors2025 · 7 citations
  3. 3Emerging CAR immunotherapies: broadening therapeutic horizons beyond cancer2025 · 10 citations
  4. 4Precision sniper for solid tumors: CAR-NK cell therapy2025 · 15 citations
  5. 5From Bench to Bedside: Emerging Paradigms in CAR‐T Cell Therapy for Solid Malignancies2025 · 7 citations